NCT04108624 2026-04-03
Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
University of Chicago
Phase NA Active not recruiting
Clinical Trials
14 trialsNCT06073353 2026-03-11
THRIVE-M
Massachusetts General Hospital
Phase NA Active not recruiting
NCT05587972 2026-02-23
Real World Treatment Experience of Patients With Breast, Lung, or GI Cancer or Multiple Myeloma Using Remote Symptom Monitoring
Carevive Systems, Inc.
Phase NA Active not recruiting
NCT03141437 2025-10-14
Decision Aid Website in Helping to Make Decisions About Fertility in Participants With Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT03389347 2025-09-22
High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
University of Washington
Phase NA Active not recruiting
NCT05871008 2025-09-15
Integrated Actionable Aging Assessment for Cancer Patients Pilot
University of Colorado, Denver
Phase NA Active not recruiting
NCT05831358 2025-08-17
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
Case Comprehensive Cancer Center
Phase NA Active not recruiting
NCT06328699 2025-08-15
Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation
Emory University
Phase NA Active not recruiting
NCT07088783 2025-07-28
OCARE-MM
Dokuz Eylul University
Phase NA Active not recruiting
NCT07026799 2025-06-18
GMMG-HD8-INDEX
University Hospital Heidelberg
Phase NA Active not recruiting
NCT04000880 2025-06-12
AMPLIFY
University of Alabama at Birmingham
Phase NA Active not recruiting
NCT06924424 2025-04-11
Aponermin, Pomalidomide, Dexamethasone for Patients With Relapsed/ Refractory Multiple Myeloma
Peking University People's Hospital
Phase NA Active not recruiting
NCT02911571 2024-12-03
PROMMIS
SkylineDx
Phase NA Active not recruiting
NCT05889221 2024-09-05
Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Poitiers University Hospital
Phase NA Active not recruiting